Alzamend Neuro, Inc. $ALZN Shares Purchased by Kingsbury Capital Investment Advisors LLC

Kingsbury Capital Investment Advisors LLC lifted its position in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) by 134.5% during the second quarter, Holdings Channel.com reports. The firm owned 1,329,100 shares of the company’s stock after acquiring an additional 762,367 shares during the period. Alzamend Neuro comprises 1.3% of Kingsbury Capital Investment Advisors LLC’s investment portfolio, making the stock its 18th biggest holding. Kingsbury Capital Investment Advisors LLC owned 0.28% of Alzamend Neuro worth $1,595,000 at the end of the most recent reporting period.

Separately, DRW Securities LLC raised its holdings in Alzamend Neuro by 27.5% in the 4th quarter. DRW Securities LLC now owns 116,319 shares of the company’s stock worth $212,000 after purchasing an additional 25,074 shares during the period. Institutional investors and hedge funds own 49.61% of the company’s stock.

Alzamend Neuro Price Performance

Shares of NASDAQ ALZN opened at $1.66 on Monday. The company has a 50 day simple moving average of $1.39 and a 200-day simple moving average of $1.37. The company has a market capitalization of $8.02 million, a P/E ratio of -0.57 and a beta of 0.23. Alzamend Neuro, Inc. has a 1 year low of $0.84 and a 1 year high of $2.68.

Alzamend Neuro (NASDAQ:ALZN) last released its quarterly earnings results on Wednesday, July 22nd. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.07). As a group, research analysts expect that Alzamend Neuro, Inc. will post -1.05 EPS for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings raised Alzamend Neuro from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday, August 31st. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $28.00.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.